Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Platelets were inhibited by PFC administration and activated in response to LPS. by Heather F. Pidcoke (9023789)

Fig 2 - by Karolina Pawlak (13813008)

Loss of layer V pyramidal neurons of motor cortex. by Paolo d’Errico (494029)

“…Values are expressed as mean ± SEM. Scale bars: 5 mm in A; 50 µm in C.</p>…”

Sequence alignments of HBV from high-throughput bisulfite sequencing or different HBV genotypes. by Jiangpeng Feng (9287738)

OPTN does not affect cell proliferation. by Xiao Chen Shi (8611887)

AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study by George Zarkavelis (10817434)

“…The ORR in the per protocol population (PP) was 42.9%. Within a median follow-up of 56 months, the median PFS and OS in the ITT population was 5.0 and 8.7 months, respectively. …”

Table 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”

Image 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”

S1 Dataset - by Pamela Bakkabulindi (12914980)

“…At the endline, immunization coverage for the Oral Polio Vaccine third dose; Rotavirus vaccine second dose; Pneumococcal Conjugate Vaccine third dose increased in both the intervention and control health facilities. There was a decrease in coverage for the Measles-Rubella vaccine decreased in the intervention health facilities and a decrease in Bacillus Calmette–Guérin vaccine coverage in the control facilities. …”

Variable Kinetic Isotope Effect Reveals a Multistep Pathway for Protonolysis of a Pt–Me Bond by Irving D. Rettig (14117340)

“…This concentration-dependent KIE suggests a multistep reaction mechanism, eliminating the need to invoke proton tunneling. …”

Changes in the fish community at Molokini. by Kevin C. Weng (8554347)

Dose-response curve of the activity of chitosan solution (A), blank chitosan-TPP nanoparticles (B), AmB loaded chitosan-TPP nanoparticles (C) and AmB solution (pure) (D) against L. by Alaa Riezk (7037297)

HuNoV infection slows down intestinal transit. by Arno Cuvry (7405604)

“…<p><b>A)</b> Decrease of fluorescent signal over 4 hours in 5-dpf zebrafish larvae. …”

Table_5_Depletion of tet2 results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndrome.xlsx by Yaseswini Neelamraju (4509259)

“…The gene encoding ten-eleven translocation 2 (tet2), a dioxygenase enzyme that catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, is a recurrently mutated tumor suppressor gene in MDS and other myeloid malignancies. …”

Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

Anti-CCP2 concentrations at baseline (month 0 (M0)), 1 year (M12) and 3 years (M36) of follow-up according to decreasing concentrations (panel 1 and 2), increasing concentrations (... by Olivier Meyer (63787)